UNSPSC 51283208: Spiramycin

This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71ODY0V87H. European Medicines Agency schedules Spiramycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04526MIG. Spiramycin generally arises in the molecular formula C43H74N2O14.

The term SPIRAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) SPIRAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spiramycin under HS 29419000 and SITC 54139. As of Q4 2014, SPIRAMYCIN remains the US FDA Preferred Term for this commodity. Spiramycin bears US NLM identifiers UMLS ID C0037962 and NCI Concept Code C839.

UNSPSC 51283208 Spiramycin, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The four recent opportunities posted under this code solicit naloxone and drug deactivation systems, medical and first-aid supplies for emergency response, generic pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription program capabilities — none of which are spiramycin, an antibiotic used primarily in niche therapeutic applications. State and local governments are not currently sourcing spiramycin through open solicitation; the mismatch suggests either a data-tagging error in the source or that the code has been repurposed or mislabeled in the procurement system. The issuing bodies span a county health department (Seminole County, Florida), a city fire department (City of Tampa), a state health commission (Texas Health and Human Services Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP serving multiple states including Oregon), indicating broad jurisdictional interest in pharmaceutical and medical supply procurement generally.

Recent opportunities show activity in Florida, Texas, and the Minnesota-led cooperative covering multiple states, but none directly involve spiramycin procurement. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026 with response due July 26, 2023, seeks naloxone and drug deactivation systems; the City of Tampa IFB (26P00145), posted March 25, 2026 with response due March 13, 2026, covers emergency medical supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a small local business enterprise set-aside; the Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with response due March 26, 2026, establishes statewide and multi-state contracts for generic pharmaceuticals and OTC products; and the Texas HHS RFI (HHS0017013), posted April 3, 2026, explores direct-to-manufacturer prescription capabilities. Vendors pursuing pharmaceutical sales to state and local buyers should verify code classification and contact issuing bodies directly to confirm spiramycin demand before resource allocation.